Journals / Tıp Araştırmaları Dergisi / 2009 / Cilt: 7 - Sayı: 1

Cyclosporin-A induced serious hyperpotasemia: A case report

Siklosporin-A’ya bağlı ciddi hiperpotasemi: Bir olgu sunumu

Pages
54–56
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this article, a case of severe hyperpotasemia related to Cyclosporine A in a renal transplantation patient is presented.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Cyclosporine A is a fungal metabolite, that participates in the group of calcineurin inhibitors.
📊
Key Findings & Data:Because it’s a very potent immunosuppresor, it’s commonly used at organ transplantations.
💡
Conclusion & Impact:In this article, a case of severe hyperpotasemia related to Cyclosporine A in a renal transplantation patient is presented.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Cyclosporine A is a fungal metabolite, that participates in the group of calcineurin inhibitors. Because it’s a very potent immunosuppresor, it’s commonly used at organ transplantations. Some of the important adverse effects of it are nephrotoxicity, hypertension, hypertricosis, and infections. Slight-moderate degree hyperpotasemia is not rarely seen and it’s an adverse effect that can usually be controlled. However, severe hyperpotasemia due to Cyclosporine A use is a rare condition. In this article, a case of severe hyperpotasemia related to Cyclosporine A in a renal transplantation patient is presented.

Özet

Siklosporin-A kalsinörin inhibitörleri arasında yer alan bir fungal metabolittir. Oldukça potent bir immünsupressif olduğu için organ transplantasyonlarında yaygın olarak kullanılmaktadır. Önemli yan etkileri arasında nefrotoksisite, hipertansiyon, hipertrikozis ve infeksiyonlar vardır. Hafif-orta dereceli hiperpotasemi, ilacın, nadir olmayan ve genellikle kontrol altına alınabilen bir yan etkisidir. Siklosporin-A kullanımına bağlı ciddi hiperpotasemi ise nadir görülen bir durumdur. Bu yazıda, Siklosporin-A’ya bağlı ciddi hiperpotasemi gelişen renal transplantasyonlu bir hasta sunularak tedavide yapılacak değişiklikler tartışılmıştır.

🔖

Cite This Article

GÜVENCE, N., DURANAY, M., ALTAY, M., ÜRE, M., ABUŞOĞLU, C., ECEMİŞ, Z. A. (2009). Cyclosporin-A induced serious hyperpotasemia: A case report. Tıp Araştırmaları Dergisi, Cilt: 7 - Sayı: 1, 54–56. https://ajindex.com/articles/361680

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Calne RY, Thiru S, McMaster P ve ark. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet, 1978; 2: 1328-1327
  2. Hamilton DV, Evans DB, Henderson RG ve ark. ”Nephrotoxicity” and metabolic acidosis in transplant patients on cyclosporin A. Proc Eur Dial Transplant Assoc, 1981; 18: 400-407
  3. Defronzo RA, Goldberg M, Cooke CR ve ark. Investigations into the mechanisms of hyperkalemia following renal transplantation. Kidney Int, 1977; 11: 357-365
  4. Kamel KS, Ethier JH, Quaggin S ve ark. Studies to determine the basis for hyperkalemia in recipients of a renal transplant who are treated with cyclosporine. J Am Soc Nephrol, 1991; 2: 1279-1284
  5. Foley RJ, Hamner RW, Weinman EJ. Serum potassium concentrations in cyclosporine and azathioprine- treated renal transplant patients. Nephron, 1985; 40: 280-285
  6. Zazgornik J, Shaheen FAM, Kopsa H, Biesenbach G, Kaiser W, Waldhausl W. Severe hyperkalaemia, hyperchloraemia, hyporeninaemia and hyperaldosteronism in a cyclosporine-treated Renal-transplant patient. Nephrol Dial Transplant,1988; 3: 826-829
  7. Flechner SM, Goldfarb D, Modlin C ve ark. Kidney Transplantation without calcineurin inhibitor drugs: A prospective, randomized trial of sirolimus versus cyclosporin. Tranplantation, 2002; 74; 1070-1076
  8. Adu D, Mıcheal J, Turney J, Mcmaster P. Hyperkalaemıa in cyclosporin-treated renal allograft recipients. Lancet, 1981;13:370-372
  9. Laine J, Holmberg C. Renal and adrenal mechanism in cyclosporine-induced hyperkalaemia after renal transplantation. Eur J Clin Invest, 1995; 25: 670-676
  10. Sehgal SN, Molnar-Kimber K, Ocain TD, Weichman BM. Rapamycin: a novel immunosuppresive macrolide. Med Res Rev, 1994; 14: 1-22
  11. Gonwa TA, Hrick DE, Brinker K, Grinyo JM, Schena FP. for the sirolimus renal function study group: Improved renal function in sirolimus-treated renal tranplant patients after early cyclosporine elimination. Transplantation, 2002; 74: 1560-1567
  12. Abromowicz D, Manas D, Lao M, ve ark. for the cyclosporine withdrawal study group: Cyclosporine withdrawal from a mycophenolate mofetil containing immunosuppressive regimen in stable kidney transplant recipients: A randomized, controlled study. Transplantation, 2002; 74: 1725-1734
  13. Oberbauer R, Kreis H, Johnson RWG, ve ark.For the Rapamune maintenance study group. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal trasnplant recipients: 2 year results of the rapamune mai